$SYRE
Spyre Therapeutics, Inc.

2018 Q1 Form 10-Q Financial Statement

#000156459018011484 Filed on May 08, 2018

View on sec.gov

Income Statement

Concept 2018 Q1 2017 Q1 2016 Q4
Revenue $1.510M $982.0K $1.247M
YoY Change 53.77% 14.32% -21.32%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.890M $2.360M $2.050M
YoY Change 22.46% 28.96% 26.54%
% of Gross Profit
Research & Development $6.870M $4.949M $4.740M
YoY Change 38.82% 37.63% 19.4%
% of Gross Profit
Depreciation & Amortization $70.00K $52.00K $30.00K
YoY Change 34.62% 79.31% 0.0%
% of Gross Profit
Operating Expenses $9.755M $7.313M $6.790M
YoY Change 33.39% 34.78% 21.68%
Operating Profit -$8.245M -$6.331M -$5.543M
YoY Change 30.23% 38.62% 38.68%
Interest Expense $140.0K $100.0K $70.00K
YoY Change 40.0% 233.33% 600.0%
% of Operating Profit
Other Income/Expense, Net $126.0K $84.00K -$10.00K
YoY Change 50.0% 320.0%
Pretax Income -$8.120M -$6.250M -$5.480M
YoY Change 29.92% 37.36% 37.34%
Income Tax
% Of Pretax Income
Net Earnings -$8.119M -$6.247M -$5.483M
YoY Change 29.97% 37.39% 37.52%
Net Earnings / Revenue -537.68% -636.15% -439.7%
Basic Earnings Per Share
Diluted Earnings Per Share -$487.1K -$467.5K -$409.9K
COMMON SHARES
Basic Shares Outstanding 13.45M 13.43M
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q1 2017 Q1 2016 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $43.50M $57.90M $63.50M
YoY Change -24.87% 99.66% 91.84%
Cash & Equivalents $10.76M $16.80M $47.75M
Short-Term Investments $32.70M $41.10M $15.80M
Other Short-Term Assets $2.000M $1.500M $1.700M
YoY Change 33.33% -67.39% -51.43%
Inventory
Prepaid Expenses
Receivables $3.400M $1.000M $1.200M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $48.80M $60.30M $66.42M
YoY Change -19.07% 71.31% 73.49%
LONG-TERM ASSETS
Property, Plant & Equipment $800.0K $800.0K $599.0K
YoY Change 0.0% 166.67% 72.13%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $100.0K $100.0K $40.00K
YoY Change 0.0% 100.0%
Total Long-Term Assets $1.000M $1.000M $639.0K
YoY Change 0.0% 233.33% 73.64%
TOTAL ASSETS
Total Short-Term Assets $48.80M $60.30M $66.42M
Total Long-Term Assets $1.000M $1.000M $639.0K
Total Assets $49.80M $61.30M $67.06M
YoY Change -18.76% 72.68% 73.5%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $800.0K $300.0K $168.0K
YoY Change 166.67% -40.0% -4.55%
Accrued Expenses $5.000M $3.600M $3.700M
YoY Change 38.89% 9.09% 60.87%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $5.765M $4.000M $3.965M
YoY Change 44.13% 5.26% 57.15%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $101.0K $100.0K $132.0K
YoY Change 1.0% 388.89%
Total Long-Term Liabilities $101.0K $100.0K $132.0K
YoY Change 1.0% 388.89%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.765M $4.000M $3.965M
Total Long-Term Liabilities $101.0K $100.0K $132.0K
Total Liabilities $5.866M $4.100M $4.097M
YoY Change 43.07% 7.89% 60.67%
SHAREHOLDERS EQUITY
Retained Earnings -$80.63M -$45.28M
YoY Change 92.02%
Common Stock $2.000K $1.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $43.92M $57.20M $62.97M
YoY Change
Total Liabilities & Shareholders Equity $49.79M $61.30M $67.06M
YoY Change -18.78% 72.68% 73.5%

Cashflow Statement

Concept 2018 Q1 2017 Q1 2016 Q4
OPERATING ACTIVITIES
Net Income -$8.119M -$6.247M -$5.483M
YoY Change 29.97% 37.39% 37.52%
Depreciation, Depletion And Amortization $70.00K $52.00K $30.00K
YoY Change 34.62% 79.31% 0.0%
Cash From Operating Activities -$7.447M -$5.430M -$4.350M
YoY Change 37.15% 36.09% 424.1%
INVESTING ACTIVITIES
Capital Expenditures $83.00K $271.0K -$120.0K
YoY Change -69.37% 13450.0% 200.0%
Acquisitions
YoY Change
Other Investing Activities $4.790M -$25.34M $2.680M
YoY Change -118.9% 2029.41% -670.21%
Cash From Investing Activities $4.702M -$25.61M $2.560M
YoY Change -118.36% 2052.1% -601.96%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 688.0K 100.0K 0.000
YoY Change 588.0% -200.0% -100.0%
NET CHANGE
Cash From Operating Activities -7.447M -5.430M -4.350M
Cash From Investing Activities 4.702M -25.61M 2.560M
Cash From Financing Activities 688.0K 100.0K 0.000
Net Change In Cash -2.057M -30.94M -1.790M
YoY Change -93.35% 485.98% 15.48%
FREE CASH FLOW
Cash From Operating Activities -$7.447M -$5.430M -$4.350M
Capital Expenditures $83.00K $271.0K -$120.0K
Free Cash Flow -$7.530M -$5.701M -$4.230M
YoY Change 32.08% 42.81% 435.44%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2885000
CY2018Q1 us-gaap Operating Expenses
OperatingExpenses
9755000
CY2018Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-8245000
CY2018Q1 us-gaap Investment Income Net
InvestmentIncomeNet
143000
CY2018Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-17000
CY2018Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
126000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-8119000
CY2018Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2018Q1 us-gaap Common Stock Value
CommonStockValue
2000
CY2018Q1 us-gaap Revenue From Grants
RevenueFromGrants
1510000
CY2018Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6870000
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.49
CY2018Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
16672125
CY2018Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
4000
CY2018Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8115000
CY2018Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
70000
CY2017Q1 agle Payment For Discount Premium On Investments Net
PaymentForDiscountPremiumOnInvestmentsNet
-55000
CY2018Q1 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-14000
CY2017Q1 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
49000
CY2018Q1 us-gaap Share Based Compensation
ShareBasedCompensation
835000
CY2017Q1 us-gaap Share Based Compensation
ShareBasedCompensation
401000
CY2018Q1 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
30000
CY2018Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
11000
CY2017Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
5000
CY2018Q1 us-gaap Liabilities Current
LiabilitiesCurrent
5765000
CY2018Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
101000
CY2018Q1 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
5002000
CY2018Q1 us-gaap Liabilities
Liabilities
5866000
CY2018Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
124648000
CY2018Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-98000
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
43920000
CY2018Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-80632000
CY2018Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
49786000
CY2018Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2018Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2018Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2018Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2018Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
16809669
CY2018Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
16809669
CY2018Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
295000
CY2017Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-234000
CY2018Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
102000
CY2017Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-151000
CY2018Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
396000
CY2017Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
95000
CY2018Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-20000
CY2017Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-20000
CY2018Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
4702000
CY2018Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-217000
CY2017Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-87000
CY2018Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-7447000
CY2017Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-5432000
CY2018Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
83000
CY2017Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
271000
CY2017Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
32780000
CY2018Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
4785000
CY2017Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
7440000
CY2017Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-25611000
CY2018Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
688000
CY2017Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
96000
CY2018Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
688000
CY2017Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
96000
CY2018Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-2057000
CY2017Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-30947000
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
47748000
CY2017Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16801000
CY2017Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
4000
CY2018Q1 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Such management estimates include those related to accruals of research and development related costs, stock-based compensation, and certain company income tax related items. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ significantly from those estimates.</p></div>
CY2018Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">Concentration of Credit Risk</p> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents, and marketable securities. The Company&#8217;s investment policy limits investments to high credit quality securities issued by the U.S. government, U.S. government-sponsored agencies and highly rated banks, subject to certain concentration limits and restrictions on maturities. The Company&#8217;s cash, cash equivalents, and marketable securities are held by financial institutions in the United States that management believes are of high credit quality. Amounts on deposit may at times exceed federally insured limits. The Company has not experienced any losses on its deposits of cash and cash equivalents and its accounts are monitored by management to mitigate risk. The Company is exposed to credit risk in the event of default by the financial institutions holding its cash and cash equivalents and bond issuers.</p></div>
CY2018Q1 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">Reclassification</p> <p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Certain reclassifications have been made to prior period amounts to conform to current period presentation. These reclassifications did not have an impact on the Company&#8217;s results of operations or financial position as of March&#160;31, 2018 and December&#160;31, 2017.</p></div>
CY2018Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2018Q1 agle Working Capital
WorkingCapital
43100000
CY2018Q1 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
43500000
CY2018Q1 us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
0
CY2017Q1 us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
0
CY2018Q1 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2017Q1 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2018Q1 agle Number Of Subsidiary Corporations Owned
NumberOfSubsidiaryCorporationsOwned
7
CY2018Q1 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
7620000
CY2018Q1 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
7620000
CY2018Q1 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
32813000
CY2018Q1 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
98000
CY2018Q1 us-gaap Available For Sale Securities
AvailableForSaleSecurities
32715000
CY2017Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
8924000
CY2017Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
8924000
CY2017Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
102000
CY2017Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
37482000
CY2018Q1 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
32715000
CY2017Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
34498000
CY2017Q4 agle Available For Sale Securities Debt Maturities Year One Through Two Fair Value
AvailableForSaleSecuritiesDebtMaturitiesYearOneThroughTwoFairValue
2984000
CY2018Q1 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
1001000
CY2017Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
1837000
CY2018Q1 agle Accrued Contracted Research And Development Costs
AccruedContractedResearchAndDevelopmentCosts
3379000
CY2017Q4 agle Accrued Contracted Research And Development Costs
AccruedContractedResearchAndDevelopmentCosts
2552000
CY2018Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
512000
CY2017Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
672000
CY2018Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
110000
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
159000
CY2018Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
0
CY2018Q1 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
40335000
CY2017Q4 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
46406000
CY2018Q1 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0

Files In Submission

Name View Source Status
0001564590-18-011484-index-headers.html Edgar Link pending
0001564590-18-011484-index.html Edgar Link pending
0001564590-18-011484.txt Edgar Link pending
0001564590-18-011484-xbrl.zip Edgar Link pending
agle-10q_20180331.htm Edgar Link pending
agle-20180331.xml Edgar Link completed
agle-20180331.xsd Edgar Link pending
agle-20180331_cal.xml Edgar Link unprocessable
agle-20180331_def.xml Edgar Link unprocessable
agle-20180331_lab.xml Edgar Link unprocessable
agle-20180331_pre.xml Edgar Link unprocessable
agle-ex311_6.htm Edgar Link pending
agle-ex312_11.htm Edgar Link pending
agle-ex321_9.htm Edgar Link pending
agle-ex322_7.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending